Nexxen Announces November 2025 Share Repurchase Program Summary GlobeNewswire December 01, 2025 NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) — Nexxen International Ltd. (NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising technology platform with deep expertise in data and advanced TV, today announced the Company repurchased 427,500 Ordinary Shares at an average price […]
North American Niobium and Critical Minerals Corp. Launches its C$2.69 Million District-Scale Fully-Funded Comprehensive 2026 Quebec Exploration Program Focused on Niobium and Rare Earth Elements Discoveries GlobeNewswire December 01, 2025 Vancouver, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) — North America Niobium and Critical Minerals Corp. (CSE: NIOB) (FSE: IOR) (OTCQB: NIOMF) (“North American Niobium”
Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in patients with Dravet syndrome treated with zorevunersen support the potential for disease modification GlobeNewswire December 01, 2025 CAMBRIDGE, Mass and BEDFORD, Mass., Dec. 01,
Abeona Therapeutics(R) Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire December 01, 2025 CLEVELAND, Dec. 01, 2025 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium Study findings to be featured in a poster spotlight presentation GlobeNewswire December 01, 2025 HOUSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis. Results provide clinical evidence that CardiolRx™ reduces inflammation-driven structural damage in the heart, an important cause of heart failure progression. The ARCHER data
Post Holdings, Inc. (NYSE:POST) (the “Company” or “Post”) today announced it intends to commence a private offering to eligible purchasers, subject to market and other conditions, of $1,300.0 million in aggregate principal amount of senior notes due 2036 (the “Notes”). The Notes will be unsecured, senior obligations of the Company and will be guaranteed by
NEW YORK, NY / ACCESS Newswire / December 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ:AGIO) concerning possible violations of federal securities laws. On November 19, 2025, Agios reported topline results from its RISE UP Phase 3 trial of Mitapivat in
NEW YORK, NY / ACCESS Newswire / December 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of IperionX Limited ("IperionX Limited") (NASDAQ:IPX) concerning possible violations of federal securities laws. Spruce Point published a short report on November 12, 2025, expressing concerns with IperionX’s financial reporting, stating it "has identified
Surrey, British Columbia–(Newsfile Corp. – December 1, 2025) – INEO Tech Corp. (TSXV: INEO) (OTCQB: INEOF) (the “Company” or “INEO“), announces a non-brokered private placement to raise up to $2,345,000 (the “Offering”). Under the Offering, the Company will issue up to 156,355,684 common shares at $0.015 per Share. Subject to compliance with exemptions from the